MorrisonFoersterChinaLife.PDFVIP

Morrison Foerster China Life Sciences 美富律师事务所中国生命科学业务 December 2011 二零一一年十二月 China Life Sciences 中国生命科学通讯 Newsletter Welcome to the inaugural issue of our China Life Sciences Newsletter, a periodic In This Issue update on key developments, companies and people in the dynamic China life sciences industry. The goal of the newsletter is to provide companies, entrepreneurs 2 Investor QA and investors with useful information on the issues and opportunities most relevant 6 Implications of the Leahy-Smith to China life sciences businesses. America Invents Act for Chinese Life Science Companies Our issue opens with an Investor QA piece with Dr. Leon Chen of Fidelity Growth 12 Frequent Issues Arising in Acquisitions Partners Asia. Dr. Chen’s experience spans the research laboratory, management of China Life Sciences Targets consulting, and most recently, life sciences venture capital industries. Dr. Chen 16 Key Regulatory Development reviews notable trends and opportunities in the med device sector in China. Next is an article by a Morrison Foerster patent partner Peng Chen addressing implications of the Leahy-Smith America Invents Act specifically for Chinese life 目录 science companies, including the need to reevaluate patent application filing 3 投资者问与答 strategies and policies regarding public disclosure of inventions in view of the shift to first-to-file, and amendments to the test for what is considered prior art under U.S. 7 收购中国的生命科学公司目标所经常 patent law. Finally, we also feature in this inaugural issue an article highlighting key 引起的问题 points to consider when acquiring a Chinese l